Search Results

You are looking at 1 - 10 of 38 items for :

  • "acromegaly" x
Clear All
Open access

A V Dreval, I V Trigolosova, I V Misnikova, Y A Kovalyova, R S Tishenina, I A Barsukov, A V Vinogradova and B H R Wolffenbuttel

Introduction Disturbances of glucose metabolism are frequently observed in patients with acromegaly. In one of the first papers to be published on this topic, abnormal glucose tolerance was found in over 60% of patients with acromegaly (1) . The

Open access

Cecilia Follin and Sven Karlsson

Introduction Acromegaly is a rare chronic condition caused by excess growth hormone (GH) secretion – usually from a pituitary tumour – and it has an incidence rate of only 3.3 cases per million people. The mean age at diagnosis is 40 years

Open access

Pinaki Dutta, Bhuvanesh Mahendran, K Shrinivas Reddy, Jasmina Ahluwalia, Kim Vaiphei, Rakesh K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, Viral N Shah, Girish Parthan and Anil Bhansali

Introduction Acromegaly is most commonly caused by a growth hormone (GH)-producing pituitary tumor and is potentially life-threatening if untreated. Early diagnosis and treatment of acromegaly result in increased longevity and better quality of life

Open access

A J Varewijck, A J van der Lely, S J C M M Neggers, S W J Lamberts, L J Hofland and J A M J L Janssen

Introduction Acromegaly is characterized by excess secretion of growth hormone (GH) causing multisystem-associated morbidities and increased mortality. GH is considered as the main regulator of circulating total insulin-like growth factor 1 (IGF1

Open access

Elena Valassi, Natalia García-Giralt, Jorge Malouf, Iris Crespo, Jaume Llauger, Adolfo Díez-Pérez and Susan M Webb

of bone matrix and bone mass ( 1 ). Acromegaly (ACRO) is a rare disease caused by excessive GH production from a pituitary adenoma ( 4 ). Chronic elevation of GH and IGF1 in ACRO is associated with severe cardiovascular, respiratory and metabolic

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

Introduction Acromegaly is a rare, classical endocrine disorder that is due to chronic excess secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) that has a prevalence of 1 in 8000–14,000 of the population ( 1 , 2 , 3

Open access

Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen and on behalf of the Growth Hormone Research Society

factor-I (IGF-I). Both are used diagnostically; IGF-I is used to monitor the effects of GH replacement in GH deficiency (GHD), and both GH and IGF-I are used in the diagnosis and management of acromegaly. While serum IGF-I level is used as a surrogate

Open access

Anna-Pauliina Iivonen, Johanna Känsäkoski, Atte Karppinen, Leena Kivipelto, Camilla Schalin-Jäntti, Auli Karhu and Taneli Raivio

inputs such as growth hormone-releasing hormone (GHRH) and somatostatin as well as several peripheral hormones. GH-secreting pituitary adenomas, i.e. somatotropinomas, lead to acromegaly in adults and (acro-) gigantism in children and adolescents

Open access

Julie M Silverstein

Introduction Acromegaly is a rare hormonal condition that develops most commonly from benign somatotroph pituitary adenomas and has a prevalence of 36–69 cases per million and an incidence of 3–4 cases per million per year (1, 2, 3, 4) . However

Open access

Marko Stojanovic, Zida Wu, Craig E Stiles, Dragana Miljic, Ivan Soldatovic, Sandra Pekic, Mirjana Doknic, Milan Petakov, Vera Popovic, Christian Strasburger and Márta Korbonits

-secreting macroadenomas, resistant to somatostatin analogue (SA) treatment ( 17 , 18 ). AIP is thought to play an important role in the response to SA in acromegaly ( 19 ). Neither the exact mechanism of AIP influence on proliferation inhibition, nor its possible role in